BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026

BioLife Solutions (NASDAQ: BLFS) will report Q4 and full-year 2025 financial results on February 26, 2026 and hold a conference call and live webcast at 4:30pm ET (1:30pm PT).

Rhea-AI Summary

BioLife Solutions (NASDAQ: BLFS) will report Q4 and full-year 2025 financial results on February 26, 2026 and hold a conference call and live webcast at 4:30pm ET (1:30pm PT).

Investors can access the live webcast on the company Investor Relations website and a replay will be archived for 90 days.

Argus Feb 17 session

+0.58% close to close Open Argus

Details

News Market Reaction – BLFS

In the Feb 17 session, BLFS gained 0.58%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement set expectations for BioLife Solutions’ fourth quarter and full year 2025 earnings...

Analysis

This announcement set expectations for BioLife Solutions’ fourth quarter and full year 2025 earnings release on February 26, 2026, when management planned to review financial performance and provide a business update. Recent history showed strong revenue growth and strategic moves, including asset sales and partnerships, yet shares often traded lower after news. Investors evaluating this event would likely focus on the finalized 2025 figures, updated guidance, and any changes in strategic priorities discussed on the call.

Key Figures

Q4 2025 revenue (cont.): $24.8M Q4 2024 revenue (cont.): $20.7M FY 2025 revenue (cont.): $96.2M +5 more

Q4 2025 revenue (cont.)

$24.8M

Preliminary unaudited revenue from continuing operations, Q4 2025

Q4 2024 revenue (cont.)

$20.7M

Revenue from continuing operations, Q4 2024

FY 2025 revenue (cont.)

$96.2M

Preliminary unaudited revenue from continuing operations, full year 2025

FY 2024 revenue (cont.)

$74.6M

Revenue from continuing operations, full year 2024

Q3 2025 total revenue

$28.1M

Reported total revenue, Q3 2025

Q3 2025 adjusted EBITDA

$7.8M

Adjusted EBITDA, 28% of revenue, Q3 2025

T. Rowe Price stake

10.8%

Beneficial ownership of BLFS common stock as of Dec 31, 2025

Invesco stake

8.2%

Beneficial ownership of BLFS common stock per Schedule 13G/A

Historical Context

5 past events · Latest: Feb 12

5 events

1. Feb 12

   Supply agreement

   24h Move

   -3.0%

   Exclusive and non-exclusive Qkine cytokine distribution deal for CGT market.

2. Jan 12

   Prelim revenue update

   24h Move

   -3.3%

   Preliminary Q4 and FY 2025 revenue growth above raised guidance range.

3. Nov 20

   Facility opening

   24h Move

   -0.7%

   Launch of Aby J. Mathew Center to support biopreservation R&D and training.

4. Nov 17

   Conference participation

   24h Move

   -0.3%

   Participation in multiple late-2025 investor conferences and updated presentation.

5. Nov 06

   Q3 2025 earnings

   24h Move

   -2.0%

   Strong Q3 cell processing growth, higher guidance, and evo business sale.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cell and gene therapy, cgt

2 terms

cell and gene therapy medical

"developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market"

Therapies that use living cells or altered genes to treat or cure disease by repairing, replacing or reprogramming parts of the body; think of it as swapping or reprogramming malfunctioning hardware or software inside the body. Investors watch these treatments closely because they can command high prices and offer one-time or long-lasting benefits, but they also carry big development costs, complex manufacturing and regulatory risks that can cause large swings in a company’s value.

cgt medical

"products and services for the cell and gene therapy ("CGT") market"

CGT stands for capital gains tax, a tax on the profit an investor realizes when selling an asset such as stocks, property, or funds. It matters because it reduces the money you actually keep from a sale—like having to share part of a prize—so investors consider tax rates, how long they hold an asset, and timing of sales to maximize after-tax returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2025 fourth quarter and full year financial results will be released on February 26, 2026. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update.

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers.  A webcast replay will be available approximately two hours after the call and will be archived on https://investors.biolifesolutions.com for 90 days.

About BioLife Solutions
BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.

Media & Investor Relations

At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com 

Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-update-on-february-26-2026-302688869.html

SOURCE BioLife Solutions, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will BioLife Solutions (BLFS) release Q4 and full-year 2025 results?

BioLife Solutions will release Q4 and full-year 2025 results on February 26, 2026. According to the company, management will summarize financial performance and provide a general business update during the scheduled conference call and webcast that afternoon.

How can investors join the BioLife Solutions (BLFS) earnings call on February 26, 2026?

Investors can join the earnings call by dialing 1-833-630-0431 (toll-free) or 1-412-317-1808 for international access. According to the company, a simultaneous live webcast will be available on its Investor Relations website.

What time is the BioLife Solutions (BLFS) webcast and where is it hosted?

The webcast begins at 4:30pm ET (1:30pm PT) on February 26, 2026. According to the company, the live stream will be hosted on the BioLife Investor Relations website with a replay archived for 90 days.

Will there be a replay of the BioLife Solutions (BLFS) February 26, 2026 call?

Yes. A webcast replay will be available approximately two hours after the call and will be archived for 90 days. According to the company, the replay can be accessed via the Investor Relations site for later review by investors.

What will BioLife Solutions (BLFS) management cover during the February 26, 2026 call?

Management will review the company's financial results and provide a general business update during the call. According to the company, the discussion will focus on Q4 and full-year 2025 performance and related operational highlights.